InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: blu_1 post# 123236

Thursday, 10/05/2017 11:24:55 AM

Thursday, October 05, 2017 11:24:55 AM

Post# of 462032

...3 month trials for Rett and Parkinsons. Will that be enough time...


I agree, AVXL's outperformance / value proposition becomes clearer with time. Shorter duration trials are likelier to be clouded by placebo effect. Many of these tests are subjective caregiver assessments. That's why Axovant had little chance for an adjunct with weak clinical effect no matter how much they powered it.
With Rett's kids' bodies are more germinal and hopefully any potential response will be rapid.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News